PHMMF

Pharma Mar SAU

PHMMF, USA

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, China, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata for the treatment of soft tissue sarcoma and recurrent ovarian cancer; Aplidin that is extracted from the ascidian Aplidium albicans for the treatment of relapsed multiple myeloma; and Zepzelca, a synthetic compound derived from a colonial ascidian to treat patients with metastatic small cell lung cancer, as well as in Phase IIb/III trials for the treatment of metastatic leiomyosarcoma. The company is also developing Ecubectedin (PM14), which is in phase I/II clinical trials with ecubectedin attained the optimal dose for the treatment of advanced solid tumors, as well as in Phase Ib trial with ecubectedin in combination with atezolizumab for the treatment of advanced solid tumors; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; and SYL1801 that is in phase II clinical trials for treating and preventing choroidal neovascularization, such as age-related macular degeneration (AMD) and diabetic retinopathy. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.

https://www.pharmamar.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PHMMF
stock
PHMMF

Three European High Growth Tech Stocks To Watch Yahoo Finance

Read more →
PHMMF
stock
PHMMF

TR | OpenAI - 4o Maintains PHARMA MAR SA(PHMMF.US) With Hold Rating, Raises Target Price to $103.15 富途资讯

Read more →

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Low

37.67

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

6.79

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-2.08 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-1.20 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

43.44 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Medium

0.71

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Pharma Mar SAU

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

2.37

Latest Release

Date

2025-09-30

EPS Actual

-0.2748

EPS Estimate

-0.15

EPS Difference

-0.1248

Surprise Percent

-83.2%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4.5)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(6.3)
GARP
Fair GARP(3.5)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(6)
Net Net
Possible Net-Net(4)
Quality
Moderate Quality(4)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.